Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Non-Current Deffered Revenue (2016 - 2024)

BioCorRx's Non-Current Deffered Revenue history spans 12 years, with the latest figure at $4045.0 for Q1 2024.

  • For Q1 2024, Non-Current Deffered Revenue changed 0.0% year-over-year to $4045.0; the TTM value through Mar 2024 reached $4045.0, changed 0.0%, while the annual FY2023 figure was $4045.0, 0.0% changed from the prior year.
  • Non-Current Deffered Revenue for Q1 2024 was $4045.0 at BioCorRx, roughly flat from $4045.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $370023.0 in Q3 2020 and bottomed at $4045.0 in Q4 2022.
  • The 5-year median for Non-Current Deffered Revenue is $19954.0 (2022), against an average of $53492.5.
  • The largest annual shift saw Non-Current Deffered Revenue surged 165.05% in 2020 before it crashed 89.16% in 2022.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $65560.0 in 2020, then crashed by 43.1% to $37301.0 in 2021, then plummeted by 89.16% to $4045.0 in 2022, then changed by 0.0% to $4045.0 in 2023, then changed by 0.0% to $4045.0 in 2024.
  • Per Business Quant, the three most recent readings for BICX's Non-Current Deffered Revenue are $4045.0 (Q1 2024), $4045.0 (Q4 2023), and $4045.0 (Q3 2023).